FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Nicholas Bodor

Research Profile

Living Beings

Anatomy

Brain

Occupations

Drug Design

Procedures

Concepts & Ideas

Chemicals & Drugs

Co-author Network

Publications

TOP 3
Whei-Mei Wu; J Howes; E T Bodor; Nicholas Bodor
The effects of delta1-cortienic acid on skin blanching, pharmacokinetics and stability of loteprednol etabonate.
E Pinto; B Zhang; S Song; Nicholas Bodor; Peter Buchwald; manish Issar
Feasibility of localized immunosuppression: 2. PLA microspheres for the sustained local delivery of a soft immunosuppressant.
Whei-Mei Wu; Y Tang; Peter Buchwald; Nicholas Bodor
Pharmacokinetics and delta1-cortienic acid excretion after intravenous administration of prednisolone and loteprednol etabonate in rats.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Nicholas Bodor (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Whei-Mei Wu; J Howes; E T Bodor; Nicholas Bodor
The effects of delta1-cortienic acid on skin blanching, pharmacokinetics and stability of loteprednol etabonate.
Die Pharmazie 2012;67(5):406-10.
2010: E Pinto; B Zhang; S Song; Nicholas Bodor; Peter Buchwald; manish Issar
Feasibility of localized immunosuppression: 2. PLA microspheres for the sustained local delivery of a soft immunosuppressant.
Die Pharmazie 2010;65(6):429-35.
2010: Whei-Mei Wu; Y Tang; Peter Buchwald; Nicholas Bodor
Pharmacokinetics and delta1-cortienic acid excretion after intravenous administration of prednisolone and loteprednol etabonate in rats.
Die Pharmazie 2010;65(6):412-6.
2010: Nicholas Bodor; Peter Buchwald
Recent advances in retrometabolic drug design (RMDD) and development.
Die Pharmazie 2010;65(6):395-403.
2008: M Patthy; G Seres; E Tóth-Sarudy; I Hazai; István Pallagi; A Simay; Nicholas Bodor
Determination of estredox, a compound with sustained estradiol function, and its impurity profile by HPLC.
Die Pharmazie 2008;63(3):210-6.
2008: Whei-Mei Wu; Jiaxiang Wu; Nobuhiro Mori; Peter Buchwald; Nicholas Bodor
Stereoisomers of N-substituted soft anticholinergics and their zwitterionic metabolite based on glycopyrrolate--syntheses and pharmacological evaluations.
Die Pharmazie 2008;63(3):200-9.
2008: Whei-Mei Wu; Fenglei Huang; Yangsuk Lee; Peter Buchwald; Nicholas Bodor
Pharmacokinetics of the sequential metabolites of loteprednol etabonate in rats.
The Journal of pharmacy and pharmacology 2008;60(3):291-7.
2007: Nicholas Bodor; E Tóth-Sarudy; T Holm; István Pallagi; E Vass; Peter Buchwald; U Langel
Novel, cell-penetrating molecular transporters with flexible backbones and permanently charged side-chains.
The Journal of pharmacy and pharmacology 2007;59(8):1065-76.
2006: Peter Buchwald; Nicholas Bodor
Soft quaternary anticholinergics: comprehensive quantitative structure-activity relationship (QSAR) with a linearized biexponential (LinBiExp) model.
Journal of medicinal chemistry 2006;49(3):883-91.
2006: Nobuhiro Mori; Peter Buchwald; Whei-Mei Wu; Fubao Ji; Günther Hochhaus; Nicholas Bodor
Pharmacological effects of some newly developed soft anticholinergics and a receptor-binding QSAR study.
Die Pharmazie 2006;61(2):148-53.
2006: I Sziráki; K Horváth; Nicholas Bodor
Comparative evaluation of Estredox, a brain-targeted estradiol delivery system versus traditional estrogen replacement therapy.
Die Pharmazie 2006;61(2):140-3.
2006: Peter Buchwald; A Juhász; C Bell; M Pátfalusi; P Kovács; Günther Hochhaus; J Howes; Nicholas Bodor
Influence of the N-acetylation polymorphism on the metabolism of talampanel: an investigation in fasted and fed subjects genotyped for NAT2 variants.
Die Pharmazie 2006;61(2):125-34.
2006: E Tóth-Sarudy; G Tóth; István Pallagi; G Seres; B Vitális; M Tapfer; V Perczel; István Kurucz; Nicholas Bodor; Z Zubovics
Preparation and biological effects of pure stereoisomeric novel soft anticholinergics.
Die Pharmazie 2006;61(2):90-6.
2006: Nicholas Bodor; Peter Buchwald
Corticosteroid design for the treatment of asthma: structural insights and the therapeutic potential of soft corticosteroids.
Current pharmaceutical design 2006;12(25):3241-60.
2005: Whei-Mei Wu; Peter Buchwald; Nobuhiro Mori; Fubao Ji; JiaXiang Wu; Nicholas Bodor
Pharmacokinetic and pharmacodynamic evaluations of the zwitterionic metabolite of a new series of N-substituted soft anticholinergics.
Pharmaceutical research 2005;22(12):2035-44.
2005: Fubao Ji; W Wu; X Dai; Nobuhiro Mori; Jiaxiang Wu; Peter Buchwald; Nicholas Bodor
Synthesis and pharmacological effects of new, N-substituted soft anticholinergics based on glycopyrrolate.
The Journal of pharmacy and pharmacology 2005;57(11):1427-35.
2005: Peter Buchwald; Attila Juhász; Cynthia Bell; Márta Pátfalusi; John Howes; Nicholas Bodor
Unified pharmacogenetics-based parent-metabolite pharmacokinetic model incorporating acetylation polymorphism for talampanel in humans.
Journal of pharmacokinetics and pharmacodynamics 2005;32(3-4):377-400.
2005: Nicholas Bodor; Peter Buchwald
Ophthalmic drug design based on the metabolic activity of the eye: soft drugs and chemical delivery systems.
The AAPS journal 2005;7(4):E820-33.
2004: István Kurucz; Klára Németh; S Mészáros; Katalin Török; Z Nagy; Z Zubovics; K Horváth; Nicholas Bodor
Anti-inflammatory effect and soft properties of etiprednol dicloacetate (BNP-166), a new, anti-asthmatic steroid.
Die Pharmazie 2004;59(5):412-6.
2004: Peter Buchwald; Nicholas Bodor
Soft glucocorticoid design: structural elements and physicochemical parameters determining receptor-binding affinity.
Die Pharmazie 2004;59(5):396-404.
2004: M Patthy; G Seres; A Csanádi; T Szekeres; Z Zubovics; Nicholas Bodor
HPLC separation of related impurities in etiprednol dicloacetate, a novel soft corticosteroid.
Die Pharmazie 2004;59(5):382-6.
2004: G Somogyi; Peter Buchwald; Nicholas Bodor
Metabolic properties of phosphonate esters.
Die Pharmazie 2004;59(5):378-81.
2004: A Csanádi; Gy Horváth; T Szekeres; T Haskó; L Ila; J Ivanics; M Patthy; J Salát; G Seres; István Pallagi; G Tóth; F Szederkényi; A Kónya; A Tegdes; Nicholas Bodor; Z Zubovics
Etiprednol dicloacetate, a new soft glucocorticoid drug candidate. Development of chemistry.
Die Pharmazie 2004;59(5):349-59.
2004: Mariann K Tapfer; Laszlo Sebestyen; István Kurucz; Katalin Horvath; Istvan Szelenyi; Nicholas Bodor
New evidence for the selective, long-lasting central effects of the brain-targeted estradiol, Estredox.
Pharmacology, biochemistry, and behavior 2004;77(3):423-9.
2004: Nicholas Bodor; Peter Buchwald
Designing safer (soft) drugs by avoiding the formation of toxic and oxidative metabolites.
Molecular biotechnology 2004;26(2):123-32.
2003: Fenglei Huang; Clinton E Browne; Whei-Mei Wu; Attila Juhász; Fubao Ji; Nicholas Bodor
Design, pharmacokinetic, and pharmacodynamic evaluation of a new class of soft anticholinergics.
Pharmaceutical research 2003;20(10):1681-9.
2003: István Kurucz; Szilveszter Tóth; Klára Németh; Katalin Török; Viola Csillik-Perczel; Agnes Pataki; Cecilia Salamon; Zoltán Nagy; József I Székely; Katalin Horváth; Nicholas Bodor
Potency and specificity of the pharmacological action of a new, antiasthmatic, topically administered soft steroid, etiprednol dicloacetate (BNP-166).
The Journal of pharmacology and experimental therapeutics 2003;307(1):83-92.
2002: Nicholas Bodor; Peter Buchwald
Barriers to remember: brain-targeting chemical delivery systems and Alzheimer's disease.
Drug discovery today 2002;7(14):766-74.
2002: Jiaxiang Wu; Sung-Hwa Yoon; Whei-Mei Wu; Nicholas Bodor
Synthesis and biological evaluations of brain-targeted chemical delivery systems of [Nva2]-TRH.
The Journal of pharmacy and pharmacology 2002;54(7):945-50.
2002: Nicholas Bodor; Hassan H Farag; M Dulce C Barros; Whei-Mei Wu; Peter Buchwald
In vitro and in vivo evaluations of dihydroquinoline- and dihydroisoquinoline-based targetor moieties for brain-specific chemical delivery systems.
Journal of drug targeting 2002;10(1):63-71.
2002: Peter Buchwald; Nicholas Bodor
Physicochemical aspects of the enzymatic hydrolysis of carboxylic esters.
Die Pharmazie 2002;57(2):87-93.
2002: A Miklós; Z Magyar; E Kiss; I Novák; M Grósz; M Nyitray; I Dereszlay; E Czégeni; A Druga; J Howes; Nicholas Bodor
28-day oral toxicity study with soft corticosteroid BNP-166 in rats and dogs, followed by a 14-day recovery period.
Die Pharmazie 2002;57(2):142-6.
2002: Fubao Ji; Whei-Mei Wu; Nicholas Bodor
Studies on a soft glycopyrrolate analog, SG-1.
Die Pharmazie 2002;57(2):138-41.
2002: G Somogyi; Peter Buchwald; Nicholas Bodor
Targeted drug delivery to the central nervous system via phosphonate derivatives (anionic delivery system for testosterone).
Die Pharmazie 2002;57(2):135-7.
2002: Whei-Mei Wu; Jiaxiang Wu; Nicholas Bodor
Effect of 2-hydroxypropyl-beta-cyclodextrin on the solubility, stability, and pharmacological activity of the chemical delivery system of TRH analogs.
Die Pharmazie 2002;57(2):130-4.
2002: Fenglei Huang; Whei-Mei Wu; Fubao Ji; A Juhász; Nicholas Bodor
Design, pharmacokinetic, and pharmacodynamic evaluation of soft anticholinergics based on tropyl alpha-phenylcyclopentylacetate.
Die Pharmazie 2002;57(2):115-21.
2002: A Buchwald; Hartmut Derendorf; Fubao Ji; N Y Nagaraja; Whei-Mei Wu; Nicholas Bodor
Soft cannabinoid analogues as potential anti-glaucoma agents.
Die Pharmazie 2002;57(2):108-14.
2002: Nicholas Bodor; Peter Buchwald
Designing safer (soft) drugs by avoiding the formation of toxic and oxidative metabolites.
Methods in molecular biology (Clifton, N.J.) 2002;186():301-12.
2001: Peter Buchwald; Nicholas Bodor
A simple, predictive, structure-based skin permeability model.
The Journal of pharmacy and pharmacology 2001;53(8):1087-98.
2001: Nicholas Bodor; Hassan H Farag; P Polgar
A tryptamine analog with high affinity to the heart tissues is a potential antiarrhythmic agent.
The Journal of pharmacy and pharmacology 2001;53(6):889-94.
2001: Nicholas Bodor; Peter Buchwald
Drug targeting by retrometabolic design: soft drugs and chemical delivery systems.
Journal of receptor and signal transduction research 2001;21(2-3):287-310.
2001: Fenglei Huang; Peter Buchwald; Clinton E Browne; Hassan H Farag; Whei-Mei Wu; Fubao Ji; Günther Hochhaus; Nicholas Bodor
Receptor binding studies of soft anticholinergic agents.
AAPS pharmSci 2001;3(4):E30.
2000: Laszlo Prokai; Katalin Prokai-Tatrai; Nicholas Bodor
Targeting drugs to the brain by redox chemical delivery systems.
Medicinal research reviews 2000;20(5):367-416.
2000: S H Yoon; Jiaxiang Wu; Whei-Mei Wu; Laszlo Prokai; Nicholas Bodor
Brain-targeted chemical delivery of [Leu2, Pip3]-TRH: synthesis and biological evaluation.
Bioorganic & medicinal chemistry 2000;8(5):1059-63.
2000: S K Hwang; Attila Juhasz; S H Yoon; Nicholas Bodor
Soft drugs. 12. Design, synthesis, and evaluation of soft bufuralol analogues.
Journal of medicinal chemistry 2000;43(8):1525-32.
2000: Peter Buchwald; Nicholas Bodor
Structure-based estimation of enzymatic hydrolysis rates and its application in computer-aided retrometabolic drug design.
Die Pharmazie 2000;55(3):210-7.
2000: Nicholas Bodor; J Drustrup; W Wu
Effect of cyclodextrins on the solubility and stability of a novel soft corticosteroid, loteprednol etabonate.
Die Pharmazie 2000;55(3):206-9.
2000: A Buchwald; Clinton E Browne; Whei-Mei Wu; Fubao Ji; Nicholas Bodor
Soft cannabinoid analogues as potential anti-glaucoma agents.
Die Pharmazie 2000;55(3):196-201.
2000: Fubao Ji; Fenglei Huang; Attila Juhasz; W Wu; Nicholas Bodor
Design, synthesis, and pharmacological evaluation of soft glycopyrrolate and its analog.
Die Pharmazie 2000;55(3):187-91.
2000: Nicholas Bodor; S C Moon; Luis E Bruno-Blanch
Synthesis and pharmacological evaluation of prodrugs of valproic acid.
Die Pharmazie 2000;55(3):184-6.
2000: Nicholas Bodor
Recent advances in retrometabolic drug design and targeting approaches.
Die Pharmazie 2000;55(3):163-6.
2000: Nicholas Bodor; Peter Buchwald
Soft drug design: general principles and recent applications.
Medicinal research reviews 2000;20(1):58-101.
1999: Peter Buchwald; Nicholas Bodor
Quantitative structure-metabolism relationships: steric and nonsteric effects in the enzymatic hydrolysis of noncongener carboxylic esters.
Journal of medicinal chemistry 1999;42(25):5160-8.
1999: Laszlo Prokai; Katalin Prokai-Tatrai; X Ouyang; H S Kim; Whei-Mei Wu; Alevtina D Zharikova; Nicholas Bodor
Metabolism-based brain-targeting system for a thyrotropin-releasing hormone analogue.
Journal of medicinal chemistry 1999;42(22):4563-71.
1999: L F Buris; Nicholas Bodor; László Buris
Loteprednol etabonate, a new soft steroid is effective in a rabbit acute experimental model for arthritis.
Die Pharmazie 1999;54(1):58-61.
1998: Peter Buchwald; Nicholas Bodor
Octanol-water partition: searching for predictive models.
Current medicinal chemistry 1998;5(5):353-80.
1998: P Chen; Nicholas Bodor; Whei-Mei Wu; Laszlo Prokai
Strategies to target kyotorphin analogues to the brain.
Journal of medicinal chemistry 1998;41(20):3773-81.
1998: Nicholas Bodor; Peter Buchwald; M J Huang
Computer-assisted design of new drugs based on retrometabolic concepts.
SAR and QSAR in environmental research 1998;8(1-2):41-92.
1998: Peter Buchwald; Nicholas Bodor
Octanol-water partition of nonzwitterionic peptides: predictive power of a molecular size-based model.
Proteins 1998;30(1):86-99.
1997: Nicholas Bodor; Peter Buchwald
Drug targeting via retrometabolic approaches.
Pharmacology & therapeutics 1997;76(1-3):1-27.
1997: Nicholas Bodor; Hassan H Farag; G Somogyi; Whei-Mei Wu; M Dulce C Barros; Laszlo Prokai
Ocular-specific delivery of timolol by sequential bioactivation of its oxime and methoxime analogs.
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 1997;13(5):389-403.
1997: Hassan H Farag; Whei-Mei Wu; M Dulce C Barros; G Somogyi; Laszlo Prokai; Nicholas Bodor
Ocular-specific chemical delivery systems of betaxolol for safe local treatment of glaucoma.
Drug design and discovery 1997;15(2):117-30.
1997: Nicholas Bodor
Retrometabolic approaches for drug design and targeting.
Die Pharmazie 1997;52(7):491-4.
1997: A Kourounakis; Nicholas Bodor; J Simpkins
Synthesis and evaluation of brain-targeted chemical delivery systems for the neurotrophomodulator 4-methylcatechol.
The Journal of pharmacy and pharmacology 1997;49(1):1-9.
1996: Katalin Prokai-Tatrai; Laszlo Prokai; Nicholas Bodor
Brain-targeted delivery of a leucine-enkephalin analogue by retrometabolic design.
Journal of medicinal chemistry 1996;39(24):4775-82.
1996: G Brouillette; M Kawamura; G N Kumar; Nicholas Bodor
Soft drugs. 21. Design and evaluation of soft analogs of propantheline.
Journal of pharmaceutical sciences 1996;85(6):619-23.
1996: M Saah; Whei-Mei Wu; K Eberst; E Marvanyos; Nicholas Bodor
Design, synthesis, and pharmacokinetic evaluation of a chemical delivery system for drug targeting to lung tissue.
Journal of pharmaceutical sciences 1996;85(5):496-504.
1996: Indra K Reddy; Mansoor A Khan; Whei-Mei Wu; Nicholas Bodor
Permeability of a soft steroid, loteprednol etabonate, through an excised rabbit cornea.
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 1996;12(2):159-67.
1995: ME Brewster; W R Anderson; Thorsteinn Loftsson; M J Huang; Nicholas Bodor; E Pop
Preparation, characterization, and anesthetic properties of 2-hydroxypropyl-beta-cyclodextrin complexes of pregnanolone and pregnenolone in rat and mouse.
Journal of pharmaceutical sciences 1995;84(10):1154-9.
1995: A Kourounakis; Nicholas Bodor
Quantitative structure activity relationships of catechol derivatives on nerve growth factor secretion in L-M cells.
Pharmaceutical research 1995;12(8):1199-204.
1995: ME Brewster; W R Anderson; K S Estes; Nicholas Bodor; E Pop; J A Panetta
Tissue distribution of LY231617, an antioxidant with neuroprotectant activity, in the rat.
Journal of pharmaceutical sciences 1995;84(7):791-3.
1995: Nicholas Bodor; Whei-Mei Wu; T Murakami; S Engel
Soft drugs. 19. Pharmacokinetics, metabolism and excretion of a novel soft corticosteroid, loteprednol etabonate, in rats.
Pharmaceutical research 1995;12(6):875-9.
1995: Nicholas Bodor; T Murakami; Whei-Mei Wu
Soft drugs. 18. Oral and rectal delivery of loteprednol etabonate, a novel soft corticosteroid, in rats--for safer treatment of gastrointestinal inflammation.
Pharmaceutical research 1995;12(6):869-74.
1995: Laszlo Prokai; Whei-Mei Wu; G Somogyi; Nicholas Bodor
Ocular delivery of the beta-adrenergic antagonist alprenolol by sequential bioactivation of its methoxime analogue.
Journal of medicinal chemistry 1995;38(11):2018-20.
1995: H S Yang; Whei-Mei Wu; Nicholas Bodor
Soft drugs. XX. Design, synthesis, and evaluation of ultra-short acting beta-blockers.
Pharmaceutical research 1995;12(3):329-36.
1995: Nicholas Bodor; M J Huang; J D Watts
Theoretical studies on the structures of natural and alkylated cyclodextrins.
Journal of pharmaceutical sciences 1995;84(3):330-6.
1995: Nicholas Bodor; Laszlo Prokai; Whei-Mei Wu; G Somogyi; Hassan H Farag
Sequential bioactivation of methoxime analogs of beta-adrenergic antagonists in the eye.
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 1995;11(3):305-18.
1995: ME Brewster; P J Druzgala; W R Anderson; M J Huang; Nicholas Bodor; E Pop
Efficacy of a 3-substituted versus 17-substituted chemical delivery system for estradiol brain targeting.
Journal of pharmaceutical sciences 1995;84(1):38-43.
1995: P Polgar; Nicholas Bodor
Minimal cardiac electrophysiological activity of alprenoxime, a site-activated ocular beta-blocker, in dogs.
Life sciences 1995;56(14):1207-13.
1994: ME Brewster; M S Bartruff; W R Anderson; P J Druzgala; Nicholas Bodor; E Pop
Effect of molecular manipulation on the estrogenic activity of a brain-targeting estradiol chemical delivery system.
Journal of medicinal chemistry 1994;37(24):4237-44.
1994: W R Anderson; M Brewster; E Pop; K S Estes; Nicholas Bodor
Improved parenteral formulations for traditional antiepileptics.
PDA journal of pharmaceutical science and technology / PDA 1994;48(6):333-5.
1994: Indra K Reddy; Nicholas Bodor
In vitro evaluation of a controlled-release site-specific diisovaleryl tert-butalone chemical delivery system for the eye.
Journal of pharmaceutical sciences 1994;83(3):450-3.
1994: Nicholas Bodor
Designing safer ophthalmic drugs by soft drug approaches.
Journal of ocular pharmacology 1994;10(1):3-15.
1994: F A Omar; H H Farag; Nicholas Bodor
Synthesis and evaluation of a redox chemical delivery system for brain-enhanced dopamine containing an activated carbamate-type ester.
Journal of drug targeting 1994;2(4):309-16.
1993: G N Kumar; R H Hammer; Nicholas Bodor
Soft drugs--XVI. Design, evaluation and transdermal penetration of novel soft anticholinergics based on methatropine.
Bioorganic & medicinal chemistry 1993;1(5):327-32.
1993: ME Brewster; E Pop; A J Braunstein; A C Pop; P Druzgala; A Dinculescu; W Anderson; A Elkoussi; Nicholas Bodor
The effect of dihydronicotinate N-substitution on the brain-targeting efficacy of a zidovudine chemical delivery system.
Pharmaceutical research 1993;10(9):1356-62.
1993: R H Hammer; E Gunes; G N Kumar; Whei-Mei Wu; V Srinivasan; Nicholas Bodor
Soft drugs--XIV. Synthesis and anticholinergic activity of soft phenylsuccinic analogs of methatropine.
Bioorganic & medicinal chemistry 1993;1(3):183-7.
1993: G N Kumar; R H Hammer; Whei-Mei Wu; Nicholas Bodor
Soft drugs 15: mydriatic activity and transcorneal penetration of phenylsuccinic soft analogs of methscopolamine as short acting mydriatics.
Current eye research 1993;12(6):501-6.
1993: G N Kumar; R H Hammer; Nicholas Bodor
Soft drugs. 12: Design, syntheses and evaluation of soft anticholinergics.
Drug design and discovery 1993;10(1):11-21.
1993: G N Kumar; R H Hammer; Nicholas Bodor
Soft drugs. 13: Design and evaluation of phenylsuccinic analogs of scopolamine as soft anticholinergics.
Drug design and discovery 1993;10(1):1-9.
1993: Nicholas Bodor
Design of novel soft corticosteroids.
Current problems in dermatology 1993;21():11-9.
1993: S H Yoon; Nicholas Bodor; James W Simpkins
Synthesis and in vitro dopaminergic activity of (2-aminoethyl)-1-hydroxy-2-pyridone type dopamine analogs.
Drug design and discovery 1993;10(1):35-44.
1992: Günther Hochhaus; L S Chen; A Ratka; P Druzgala; J Howes; Nicholas Bodor; Hartmut Derendorf
Pharmacokinetic characterization and tissue distribution of the new glucocorticoid soft drug loteprednol etabonate in rats and dogs.
Journal of pharmaceutical sciences 1992;81(12):1210-5.
1992: Nicholas Bodor; Thorsteinn Loftsson; Whei-Mei Wu
Metabolism, distribution, and transdermal permeation of a soft corticosteroid, loteprednol etabonate.
Pharmaceutical research 1992;9(10):1275-8.
1992: Nicholas Bodor; Laszlo Prokai; Whei-Mei Wu; Hassan H Farag; S Jonalagadda; M Kawamura; J Simpkins
A strategy for delivering peptides into the central nervous system by sequential metabolism.
Science (New York, N.Y.) 1992;257(5077):1698-700.
1992: Nicholas Bodor; M J Huang
A new method for the estimation of the aqueous solubility of organic compounds.
Journal of pharmaceutical sciences 1992;81(9):954-60.
1992: Nicholas Bodor; N Bodor; Whei-Mei Wu
A comparison of intraocular pressure elevating activity of loteprednol etabonate and dexamethasone in rabbits.
Current eye research 1992;11(6):525-30.
1992: Nicholas Bodor; M J Huang
An extended version of a novel method for the estimation of partition coefficients.
Journal of pharmaceutical sciences 1992;81(3):272-81.
1991: Günther Hochhaus; P Druzgala; R Hochhaus; M J Huang; Nicholas Bodor
Glucocorticoid activity and structure activity relationships in a series of some novel 17 alpha-ether-substituted steroids: influence of 17 alpha-substituents.
Drug design and discovery 1991;8(2):117-25.
1991: Nicholas Bodor; A Elkoussi
Improved delivery through biological membranes. LVI. Pharmacological evaluation of alprenoxime--a new potential antiglaucoma agent.
Pharmaceutical research 1991;8(11):1389-95.
1991: P Druzgala; Nicholas Bodor
Regioselective O-alkylation of cortienic acid and synthesis of a new class of glucocorticoids containing a 17 alpha-alkoxy, a 17 alpha-(1'-alkoxyethyloxy), a 17 alpha-alkoxymethyloxy, or a 17 alpha-methylthiomethyloxy function.
Steroids 1991;56(9):490-4.
1991: ME Brewster; W Anderson; Nicholas Bodor
Brain, blood, and cerebrospinal fluid distribution of a zidovudine chemical delivery system in rabbits.
Journal of pharmaceutical sciences 1991;80(9):843-6.
1991: K S Estes; V Keuth; K Dietzel; ME Brewster; Nicholas Bodor; Hartmut Derendorf
A redox-based chemical delivery system that enhances estradiol distribution to the brain: disposition studies in the rat.
Pharmaceutical research 1991;8(9):1180-5.
1991: E Pop; Thorsteinn Loftsson; Nicholas Bodor
Solubilization and stabilization of a benzylpenicillin chemical delivery system by 2-hydroxypropyl-beta-cyclodextrin.
Pharmaceutical research 1991;8(8):1044-9.
1991: W R Anderson; M H Rahimy; ME Brewster; Nicholas Bodor; James W Simpkins
The effects of a brain-enhanced estradiol delivery system on testosterone and androgen-dependent tissues. II. The role of testosterone.
Endocrinology 1991;129(2):726-33.
1991: M H Rahimy; W R Anderson; ME Brewster; Nicholas Bodor; James W Simpkins
The effects of a brain-enhanced estradiol delivery system on testosterone and androgen-dependent tissues. I. Dose-response and time-course evaluation.
Endocrinology 1991;129(2):717-25.
1991: Nicholas Bodor; S T Kiss-Buris; László Buris
Novel soft steroids: effects on cell growth in vitro and on wound healing in the mouse.
Steroids 1991;56(8):434-9.
1991: ME Brewster; M S Hora; James W Simpkins; Nicholas Bodor
Use of 2-hydroxypropyl-beta-cyclodextrin as a solubilizing and stabilizing excipient for protein drugs.
Pharmaceutical research 1991;8(6):792-5.
1991: R H Hammer; W Wu; J S Sastry; Nicholas Bodor
Short acting soft mydriatics.
Current eye research 1991;10(6):565-70.
1991: ME Brewster; W R Anderson; K S Estes; Nicholas Bodor
Development of aqueous parenteral formulations for carbamazepine through the use of modified cyclodextrins.
Journal of pharmaceutical sciences 1991;80(4):380-3.
1991: K Prókai-Tátrai; E Pop; W Anderson; J L Lin; ME Brewster; Nicholas Bodor
Redox derivatives of tranylcypromine: syntheses, properties, and monoamine oxidase inhibitor activity of some chemical delivery systems.
Journal of pharmaceutical sciences 1991;80(3):255-61.
1991: M H Rahimy; Nicholas Bodor; James W Simpkins
Effects of a brain-enhanced estrogen delivery system on tail-skin temperature of the rat: implications for menopausal hot flush.
Maturitas 1991;13(1):51-63.
1991: P Druzgala; Günther Hochhaus; Nicholas Bodor
Soft drugs--10. Blanching activity and receptor binding affinity of a new type of glucocorticoid: loteprednol etabonate.
The Journal of steroid biochemistry and molecular biology 1991;38(2):149-54.
1991: P Polgar; Nicholas Bodor
Cardiac electrophysiologic effects of adaprolol maleate, a new beta-blocker, in closed chest dogs.
Life sciences 1991;48(16):1519-28.
1990: Whei-Mei Wu; E Pop; E Shek; R Clemmons; Nicholas Bodor
Brain and CSF specific chemical delivery systems for beta-lactam antibiotics. Study of two dihydropyridine derivatives of benzylpenicillin in rabbits and dogs.
Drug design and delivery 1990;7(1):33-43.
1990: M H Rahimy; James W Simpkins; Nicholas Bodor
Dose and time-course evaluation of a redox-based estradiol-chemical delivery system for the brain. II. Pharmacodynamic responses.
Pharmaceutical research 1990;7(11):1107-12.
1990: M H Rahimy; James W Simpkins; Nicholas Bodor
Dose and time-course evaluation of a redox-based estradiol-chemical delivery system for the brain. I. Tissue distribution.
Pharmaceutical research 1990;7(10):1061-7.
1990: W J Millard; T M Romano; Nicholas Bodor; James W Simpkins
Growth hormone (GH) secretory dynamics in animals administered estradiol utilizing a chemical delivery system.
Pharmaceutical research 1990;7(10):1011-8.
1990: E Pop; W Anderson; K Prókai-Tátrai; ME Brewster; Melvin Fregly; Nicholas Bodor
Antihypertensive activity of redox derivatives of tryptophan.
Journal of medicinal chemistry 1990;33(8):2216-21.
1990: K Dietzel; V Keuth; K S Estes; ME Brewster; Roger M Clemmons; R Vistelle; Nicholas Bodor; Hartmut Derendorf
A redox-based system that enhances delivery of estradiol to the brain: pharmacokinetic evaluation in the dog.
Pharmaceutical research 1990;7(8):879-83.
1990: Nicholas Bodor; Laszlo Prokai
Site- and stereospecific ocular drug delivery by sequential enzymatic bioactivation.
Pharmaceutical research 1990;7(7):723-5.
1990: E Pop; K Prókai-Tátrai; J D Scott; ME Brewster; Nicholas Bodor
Application of a brain-targeting chemical delivery system to 9-amino-1,2,3,4-tetrahydroacridine.
Pharmaceutical research 1990;7(6):658-64.
1990: M H Rahimy; James W Simpkins; Nicholas Bodor
Tissue distribution of a brain-enhanced chemical delivery system for estradiol.
Drug design and delivery 1990;6(1):29-40.
1990: P A Woodard; D Winwood; ME Brewster; K S Estes; Nicholas Bodor
Improved delivery through biological membranes. XXI. Brain-targeted anti-convulsive agents.
Drug design and delivery 1990;6(1):15-28.
1990: E Pop; Thorsteinn Loftsson; Nicholas Bodor
Novel central nervous system targeted semisynthetic penicillins.
Drug design and delivery 1990;5(3):221-37.
1990: Nicholas Bodor; Thorsteinn Loftsson
The effect of phosphine oxides on transdermal delivery.
Acta pharmaceutica Nordica 1990;2(2):123-6.
1989: E Pop; Whei-Mei Wu; E Shek; Nicholas Bodor
Chemical delivery systems for drugs containing an amino group: synthesis and properties of some pyridine derivatives of desipramine.
Drug design and delivery 1989;5(2):93-115.
1989: ME Brewster; K S Estes; Nicholas Bodor
Development of a non-surfactant formulation for alfaxalone through the use of chemically-modified cyclodextrins.
Journal of parenteral science and technology : a publication of the Parenteral Drug Association 1989;43(6):262-5.
1989: E Shek; T Murakami; C Nath; E Pop; Nicholas Bodor
Improved anticonvulsant activity of phenytoin by a redox brain delivery system. III: Brain uptake and pharmacological effects.
Journal of pharmaceutical sciences 1989;78(10):837-43.
1989: T Murakami; E Shek; E Pop; Nicholas Bodor
Improved anticonvulsant activity of phenytoin by a redox brain delivery system. II: Stability in buffers and biological materials.
Journal of pharmaceutical sciences 1989;78(9):732-7.
1989: E Pop; E Shek; T Murakami; Nicholas Bodor
Improved anticonvulsant activity of phenytoin by a redox brain delivery system I: Synthesis and some properties of the dihydropyridine derivatives.
Journal of pharmaceutical sciences 1989;78(8):609-16.
1989: M H Rahimy; Nicholas Bodor; James W Simpkins
A rapid, sensitive method for the simultaneous quantitation of estradiol and estradiol conjugates in a variety of tissues: assay development and evaluation of the distribution of a brain-enhanced estradiol-chemical delivery system.
Journal of steroid biochemistry 1989;33(2):179-87.
1989: E Pop; Whei-Mei Wu; Nicholas Bodor
Chemical delivery systems for some penicillinase-resistant semisynthetic penicillins.
Journal of medicinal chemistry 1989;32(8):1789-95.
1989: Whei-Mei Wu; E Pop; E Shek; Nicholas Bodor
Brain-specific chemical delivery systems for beta-lactam antibiotics. In vitro and in vivo studies of some dihydropyridine and dihydroisoquinoline derivatives of benzylpenicillin in rats.
Journal of medicinal chemistry 1989;32(8):1782-8.
1989: E Pop; Whei-Mei Wu; E Shek; Nicholas Bodor
Brain-specific chemical delivery systems for beta-lactam antibiotics. Synthesis and properties of some dihydropyridine and dihydroiosquinoline derivatives of benzylpenicillin.
Journal of medicinal chemistry 1989;32(8):1774-81.
1989: James W Simpkins; W R Anderson; R Dawson; Nicholas Bodor
Effects of a brain-enhanced chemical delivery system for estradiol on body weight and food intake in intact and ovariectomized rats.
Pharmaceutical research 1989;6(7):592-600.
1988: ME Brewster; K S Estes; Thorsteinn Loftsson; R Perchalski; Hartmut Derendorf; G Mullersman; Nicholas Bodor
Improved delivery through biological membranes. XXXL: Solubilization and stabilization of an estradiol chemical delivery system by modified beta-cyclodextrins.
Journal of pharmaceutical sciences 1988;77(11):981-5.
1988: Nicholas Bodor; A A el-Koussi; M Kano; M M Khalifa
Soft drugs. 7. Soft beta-blockers for systemic and ophthalmic use.
Journal of medicinal chemistry 1988;31(8):1651-6.
1988: ME Brewster; K S Estes; R Perchalski; Nicholas Bodor
A dihydropyridine conjugate which generates high and sustained levels of the corresponding pyridinium salt in the brain does not exhibit neurotoxicity in cynomolgus monkeys.
Neuroscience letters 1988;87(3):277-82.
1988: W R Anderson; James W Simpkins; ME Brewster; Nicholas Bodor
Brain-enhanced delivery of testosterone using a chemical delivery system complexed with 2-hydroxypropyl-beta-cyclodextrin.
Drug design and delivery 1988;2(4):287-98.
1988: Nicholas Bodor; A elKoussi
Novel 'soft' beta-blockers as potential safe antiglaucoma agents.
Current eye research 1988;7(4):369-74.
1988: G Mullersman; Hartmut Derendorf; ME Brewster; K S Estes; Nicholas Bodor
High-performance liquid chromatographic assay of a central nervous system (CNS)-directed estradiol chemical delivery system and its application after intravenous administration to rats.
Pharmaceutical research 1988;5(3):172-7.
1988: R H Hammer; K Amin; Z E Gunes; G Brouillette; Nicholas Bodor
Novel 'soft' anticholinergic agents.
Drug design and delivery 1988;2(3):207-19.
1988: W R Anderson; James W Simpkins; ME Brewster; Nicholas Bodor
Evidence for suppression of serum LH without elevation in serum estradiol or prolactin with a brain-enhanced redox delivery system for estradiol.
Life sciences 1988;42(16):1493-502.
1988: K S Estes; ME Brewster; Nicholas Bodor
A redox system for brain targeted estrogen delivery causes chronic body weight decrease in rats.
Life sciences 1988;42(10):1077-84.
1988: ME Brewster; K S Estes; Nicholas Bodor
Improved delivery through biological membranes. 32. Synthesis and biological activity of brain-targeted delivery systems for various estradiol derivatives.
Journal of medicinal chemistry 1988;31(1):244-9.
1988: James W Simpkins; W R Anderson; R Dawson; A Seth; M Brewster; K S Estes; Nicholas Bodor
Chronic weight loss in lean and obese rats with a brain-enhanced chemical delivery system for estradiol.
Physiology & behavior 1988;44(4-5):573-80.
1988: W R Anderson; James W Simpkins; ME Brewster; Nicholas Bodor
Effects of a brain-enhanced chemical delivery system for estradiol on body weight and serum hormones in middle-aged male rats.
Endocrine research 1988;14(2-3):131-48.
1988: Nicholas Bodor; A ElKoussi; M Kano; T Nakamura
Improved delivery through biological membranes. 26. Design, synthesis, and pharmacological activity of a novel chemical delivery system for beta-adrenergic blocking agents.
Journal of medicinal chemistry 1988;31(1):100-6.
1987: Peter W Stacpoole; M G Gonzalez; J Vlasak; Y Oshiro; Nicholas Bodor
Dichloroacetate derivatives. Metabolic effects and pharmacodynamics in normal rats.
Life sciences 1987;41(18):2167-76.
1987: Thorsteinn Loftsson; N Gildersleeve; Nicholas Bodor
The effect of vehicle additives on the transdermal delivery of nitroglycerin.
Pharmaceutical research 1987;4(5):436-7.
1987: K S Raghavan; E Shek; Nicholas Bodor
Improved delivery through biological membranes. XXX. Synthesis and biological aspects of a 1,4-dihydropyridine based chemical delivery system for brain-sustained delivery of hydroxy CCNU.
Anti-cancer drug design 1987;2(1):25-36.
1987: A el-Koussi; Nicholas Bodor
Improved delivery through biological membranes XXV. Enhanced and sustained delivery of trifluorothymidine to the brain using a dihydropyridine in equilibrium pyridinium salt type redox delivery system.
Drug design and delivery 1987;1(4):275-83.
1987: K S Estes; ME Brewster; James W Simpkins; Nicholas Bodor
A novel redox system for CNS-directed delivery of estradiol causes sustained LH suppression in castrate rats.
Life sciences 1987;40(13):1327-34.
1986: J W Simpkins; J McCornack; K S Estes; ME Brewster; E Shek; Nicholas Bodor
Sustained brain-specific delivery of estradiol causes long-term suppression of luteinizing hormone secretion.
Journal of medicinal chemistry 1986;29(10):1809-12.
1986: Nicholas Bodor; T Nakamura; ME Brewster
Improved delivery through biological membranes. Synthesis, distribution, and neurochemical effects of a tryptamine chemical delivery system.
Drug design and delivery 1986;1(1):51-64.
1985: B B Michniak-Mikolajczak; Nicholas Bodor
A study of the penetration of five novel synthetic steroids through hairless mouse skin in vitro.
International journal of cosmetic science 1985;7(4):175-9.